Cargando…
Comparative analysis of humoral responses to BNT162b2 vaccine among patients with hematologic disorders and organ transplant recipients.
Vaccination against SARS-COV-2 is considered the most promising approach to curbing the pandemic. Patients with an immunocompromised state, such as those with hematological malignancies and organ transplantation recipients, are considered more susceptible to infection, but these at-risk patients wer...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9465495/ https://www.ncbi.nlm.nih.gov/pubmed/36100196 http://dx.doi.org/10.1016/j.trim.2022.101713 |
_version_ | 1784787810922790912 |
---|---|
author | Nakazawa, Hideyuki Sakai, Kaoko Sudo, Yuriko Iwabuchi, Ryohei Sakai, Hitoshi Nishina, Sayaka Kawakami, Toru Kawakami, Fumihiro Matsuzawa, Shuji Ito, Toshiro Kitahara, Mari Kamijo, Yuji Umemura, Takeji Ushiki, Atsuhito Kanai, Shinichiro Tsuchiya, Hiroyuki Ishida, Fumihiro |
author_facet | Nakazawa, Hideyuki Sakai, Kaoko Sudo, Yuriko Iwabuchi, Ryohei Sakai, Hitoshi Nishina, Sayaka Kawakami, Toru Kawakami, Fumihiro Matsuzawa, Shuji Ito, Toshiro Kitahara, Mari Kamijo, Yuji Umemura, Takeji Ushiki, Atsuhito Kanai, Shinichiro Tsuchiya, Hiroyuki Ishida, Fumihiro |
author_sort | Nakazawa, Hideyuki |
collection | PubMed |
description | Vaccination against SARS-COV-2 is considered the most promising approach to curbing the pandemic. Patients with an immunocompromised state, such as those with hematological malignancies and organ transplantation recipients, are considered more susceptible to infection, but these at-risk patients were underrepresented in early clinical trials for vaccination. Although a growing body of studies suggests that the humoral response to COVID-19 vaccination in each of these at-risk groups of patients may be suboptimal in comparison to healthy controls, a clinical and strategic information for the further comparative analysis among these groups is not fully described. The humoral responses after two doses of BNT162b2 vaccination were evaluated in a total of 187 patients either with allogeneic hematopoietic transplantation, with renal transplantation, with anti-CD20 antibody therapy, or with anti-CD38 antibody therapy, and in 66 healthy controls. The early response at one to three months after vaccination was significantly inferior among patients with renal transplantation, patients with anti-CD20 antibody therapy, and patients with anti-CD38 antibody therapy in comparison to healthy control. But the patients with allogeneic hematopoietic transplantation showed early humoral response comparable to healthy control. The late response at 6 months after vaccination was still suboptimal among patients with renal transplantation and patients with anti-CD20 therapy. Among our patient group, renal transplant recipients had the lowest antibody titers after vaccination regardless of timing of vaccination. Patients who had received allogeneic hematopoietic transplantation attained a comparable serological response to the control group especially if they are vaccinated >300 days after transplantation, but the response was suboptimal if the vaccination was within 300 days after transplantation. Our results may provide policy makers with critical information for the further stratification of at-risk groups, helping contribute to a better allocation of resources, including additional booster vaccination. |
format | Online Article Text |
id | pubmed-9465495 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Authors. Published by Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94654952022-09-12 Comparative analysis of humoral responses to BNT162b2 vaccine among patients with hematologic disorders and organ transplant recipients. Nakazawa, Hideyuki Sakai, Kaoko Sudo, Yuriko Iwabuchi, Ryohei Sakai, Hitoshi Nishina, Sayaka Kawakami, Toru Kawakami, Fumihiro Matsuzawa, Shuji Ito, Toshiro Kitahara, Mari Kamijo, Yuji Umemura, Takeji Ushiki, Atsuhito Kanai, Shinichiro Tsuchiya, Hiroyuki Ishida, Fumihiro Transpl Immunol Article Vaccination against SARS-COV-2 is considered the most promising approach to curbing the pandemic. Patients with an immunocompromised state, such as those with hematological malignancies and organ transplantation recipients, are considered more susceptible to infection, but these at-risk patients were underrepresented in early clinical trials for vaccination. Although a growing body of studies suggests that the humoral response to COVID-19 vaccination in each of these at-risk groups of patients may be suboptimal in comparison to healthy controls, a clinical and strategic information for the further comparative analysis among these groups is not fully described. The humoral responses after two doses of BNT162b2 vaccination were evaluated in a total of 187 patients either with allogeneic hematopoietic transplantation, with renal transplantation, with anti-CD20 antibody therapy, or with anti-CD38 antibody therapy, and in 66 healthy controls. The early response at one to three months after vaccination was significantly inferior among patients with renal transplantation, patients with anti-CD20 antibody therapy, and patients with anti-CD38 antibody therapy in comparison to healthy control. But the patients with allogeneic hematopoietic transplantation showed early humoral response comparable to healthy control. The late response at 6 months after vaccination was still suboptimal among patients with renal transplantation and patients with anti-CD20 therapy. Among our patient group, renal transplant recipients had the lowest antibody titers after vaccination regardless of timing of vaccination. Patients who had received allogeneic hematopoietic transplantation attained a comparable serological response to the control group especially if they are vaccinated >300 days after transplantation, but the response was suboptimal if the vaccination was within 300 days after transplantation. Our results may provide policy makers with critical information for the further stratification of at-risk groups, helping contribute to a better allocation of resources, including additional booster vaccination. The Authors. Published by Elsevier B.V. 2022-12 2022-09-12 /pmc/articles/PMC9465495/ /pubmed/36100196 http://dx.doi.org/10.1016/j.trim.2022.101713 Text en © 2022 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Nakazawa, Hideyuki Sakai, Kaoko Sudo, Yuriko Iwabuchi, Ryohei Sakai, Hitoshi Nishina, Sayaka Kawakami, Toru Kawakami, Fumihiro Matsuzawa, Shuji Ito, Toshiro Kitahara, Mari Kamijo, Yuji Umemura, Takeji Ushiki, Atsuhito Kanai, Shinichiro Tsuchiya, Hiroyuki Ishida, Fumihiro Comparative analysis of humoral responses to BNT162b2 vaccine among patients with hematologic disorders and organ transplant recipients. |
title | Comparative analysis of humoral responses to BNT162b2 vaccine among patients with hematologic disorders and organ transplant recipients. |
title_full | Comparative analysis of humoral responses to BNT162b2 vaccine among patients with hematologic disorders and organ transplant recipients. |
title_fullStr | Comparative analysis of humoral responses to BNT162b2 vaccine among patients with hematologic disorders and organ transplant recipients. |
title_full_unstemmed | Comparative analysis of humoral responses to BNT162b2 vaccine among patients with hematologic disorders and organ transplant recipients. |
title_short | Comparative analysis of humoral responses to BNT162b2 vaccine among patients with hematologic disorders and organ transplant recipients. |
title_sort | comparative analysis of humoral responses to bnt162b2 vaccine among patients with hematologic disorders and organ transplant recipients. |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9465495/ https://www.ncbi.nlm.nih.gov/pubmed/36100196 http://dx.doi.org/10.1016/j.trim.2022.101713 |
work_keys_str_mv | AT nakazawahideyuki comparativeanalysisofhumoralresponsestobnt162b2vaccineamongpatientswithhematologicdisordersandorgantransplantrecipients AT sakaikaoko comparativeanalysisofhumoralresponsestobnt162b2vaccineamongpatientswithhematologicdisordersandorgantransplantrecipients AT sudoyuriko comparativeanalysisofhumoralresponsestobnt162b2vaccineamongpatientswithhematologicdisordersandorgantransplantrecipients AT iwabuchiryohei comparativeanalysisofhumoralresponsestobnt162b2vaccineamongpatientswithhematologicdisordersandorgantransplantrecipients AT sakaihitoshi comparativeanalysisofhumoralresponsestobnt162b2vaccineamongpatientswithhematologicdisordersandorgantransplantrecipients AT nishinasayaka comparativeanalysisofhumoralresponsestobnt162b2vaccineamongpatientswithhematologicdisordersandorgantransplantrecipients AT kawakamitoru comparativeanalysisofhumoralresponsestobnt162b2vaccineamongpatientswithhematologicdisordersandorgantransplantrecipients AT kawakamifumihiro comparativeanalysisofhumoralresponsestobnt162b2vaccineamongpatientswithhematologicdisordersandorgantransplantrecipients AT matsuzawashuji comparativeanalysisofhumoralresponsestobnt162b2vaccineamongpatientswithhematologicdisordersandorgantransplantrecipients AT itotoshiro comparativeanalysisofhumoralresponsestobnt162b2vaccineamongpatientswithhematologicdisordersandorgantransplantrecipients AT kitaharamari comparativeanalysisofhumoralresponsestobnt162b2vaccineamongpatientswithhematologicdisordersandorgantransplantrecipients AT kamijoyuji comparativeanalysisofhumoralresponsestobnt162b2vaccineamongpatientswithhematologicdisordersandorgantransplantrecipients AT umemuratakeji comparativeanalysisofhumoralresponsestobnt162b2vaccineamongpatientswithhematologicdisordersandorgantransplantrecipients AT ushikiatsuhito comparativeanalysisofhumoralresponsestobnt162b2vaccineamongpatientswithhematologicdisordersandorgantransplantrecipients AT kanaishinichiro comparativeanalysisofhumoralresponsestobnt162b2vaccineamongpatientswithhematologicdisordersandorgantransplantrecipients AT tsuchiyahiroyuki comparativeanalysisofhumoralresponsestobnt162b2vaccineamongpatientswithhematologicdisordersandorgantransplantrecipients AT ishidafumihiro comparativeanalysisofhumoralresponsestobnt162b2vaccineamongpatientswithhematologicdisordersandorgantransplantrecipients |